AVXL vs. BASI, CGEM, FDMT, TARS, AUTL, DNA, IMTX, RLAY, PRME, and HUMA
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Bioanalytical Systems (BASI), Cullinan Therapeutics (CGEM), 4D Molecular Therapeutics (FDMT), Tarsus Pharmaceuticals (TARS), Autolus Therapeutics (AUTL), Ginkgo Bioworks (DNA), Immatics (IMTX), Relay Therapeutics (RLAY), Prime Medicine (PRME), and Humacyte (HUMA). These companies are all part of the "medical" sector.
Anavex Life Sciences (NASDAQ:AVXL) and Bioanalytical Systems (NASDAQ:BASI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability.
Anavex Life Sciences has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Bioanalytical Systems has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500.
Anavex Life Sciences received 297 more outperform votes than Bioanalytical Systems when rated by MarketBeat users. Likewise, 74.17% of users gave Anavex Life Sciences an outperform vote while only 41.03% of users gave Bioanalytical Systems an outperform vote.
Anavex Life Sciences has a net margin of 0.00% compared to Bioanalytical Systems' net margin of -7.75%. Anavex Life Sciences' return on equity of -29.04% beat Bioanalytical Systems' return on equity.
Bioanalytical Systems has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Bioanalytical Systems, indicating that it is currently the more affordable of the two stocks.
In the previous week, Anavex Life Sciences had 8 more articles in the media than Bioanalytical Systems. MarketBeat recorded 8 mentions for Anavex Life Sciences and 0 mentions for Bioanalytical Systems. Anavex Life Sciences' average media sentiment score of 1.11 beat Bioanalytical Systems' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media.
31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 10.6% of Bioanalytical Systems shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 11.5% of Bioanalytical Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Anavex Life Sciences presently has a consensus target price of $40.00, indicating a potential upside of 972.39%. Given Anavex Life Sciences' higher probable upside, equities analysts plainly believe Anavex Life Sciences is more favorable than Bioanalytical Systems.
Summary
Anavex Life Sciences beats Bioanalytical Systems on 9 of the 16 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
